Overview / Abstract: |
STATEMENT OF NEED Breast cancer accounts for nearly 30% of cancer diagnoses among women in the United States, and is the second-leading cause of cancer death in this population. Although many women benefit from regular screening as well as earlier and improved treatment, approximately 10% present with metastatic disease, and 30% with no initial lymph node involvement eventually develop metastatic disease. Women with metastatic breast cancer (MBC) have a poorer prognosis than the overall population of breast cancer patients, and issues such as refractory or resistant disease, cumulative toxicities, adverse events, depression, and financial hardship are often encountered. Despite progress in understanding the pathogenesis of MBC and advances in therapy, the 5-year overall survival rate remains only 22%. TARGET AUDIENCE Oncology nurses, nurse practitioners, clinical nurse specialists, and other health care professionals involved in the management of patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer. LEARNING OBJECTIVES Upon completion of this activity, participants should be able to: 1. Describe patient- and disease-related factors that can inform individualized treatment planning in HR-positive, HER2-negative MBC |
Expiration |
Sep 30, 2019 |
Discipline(s) |
Nurse Practitioner , Nursing CNE |
Format |
Online, Webinar / Webcast / Video |
Credits / Hours |
1.0 |
Accreditation |
ANCC |
Presenters / Authors / Faculty |
Constance Visovsky, PhD, RN, ACNP, FAAN |
Sponsors / Supporters / Grant Providers |
This activity is supported by an independent educational grant from Lilly. |
Keywords / Search Terms |
i3 Health i3 Health, breast cancer, metastatic breast cancer, MBC, HR-positive, CDK4/6 inhibitors, oncology, CE, free CE, online CE Free CE CME |